NCT05390307View on ClinicalTrials.gov

Obesity Treatment to Improve Diabetes

NACompletedINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

April 1, 2023

Primary Completion Date

January 1, 2024

Study Completion Date

January 1, 2024

Conditions
Type 1 Diabetes
Interventions
DRUG

Liraglutide / Semaglutide

Liraglutide 3mg once daily or semaglutide 1mg once weekly subcutaneous injection for 6 months.

DRUG

Dapagliflozin

Dapagliflozin 5-10 mg once daily for 6 months.

DRUG

Liraglutide or Semaglutide / Dapagliflozin

Combined treatment with Liraglutide 3mg once daily or semaglutide 1mg once weekly subcutaneous injection plus Dapagliflozin 5-10 mg once daily for 6 months.

DRUG

Liraglutide or Semaglutide / Dapagliflozin plus intensive weight loss nutrition

Liraglutide 3mg once daily or semaglutide 1mg once weekly subcutaneous injection plus Dapagliflozin 5-10 mg once daily for 6 months combined with intensive lifestyle changes.

OTHER

Usual care

Usual standard care

Trial Locations (1)

15462

Dasman Diabetes Institute, Kuwait City

All Listed Sponsors
lead

Dasman Diabetes Institute

OTHER